FDA approves SPEVIGO for generalized pustular psoriasis flares

The U.S. Food and Drug Administration has approved SPEVIGO (spesolimab-sbzo) as the first treatment option for generalized pustular psoriasis (GPP) flares in adults.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup